Hydroxyurea

Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension

Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients

A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa

Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors

Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)

Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis

Realizing Effectiveness Across Continents With Hydroxyurea (REACH)

Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

Realizing Effectiveness Across Continents With Hydroxyurea

Alternative Dosing And Prevention of Transfusions (ADAPT)